Translational AI Scientist/Engineer
BioAge Labs
Translational AI Scientist/Engineer
BioAge Labs
Clinical-stage biotech developing aging-targeted therapeutics
BioAge Labs (BIOA) is finding new ways to treat disease by targeting the mechanisms of aging, with the ultimate goal of increasing healthy human lifespan. https://bioagelabs.com
We are seeking a scientist/engineer with hands-on expertise in building generative and agentic AI systems and a strong foundation in target discovery, drug discovery and translational science. You will design and deploy AI-enabled systems that take a target and produce decision-grade, evidence-backed recommendations — from mechanism hypotheses to validation design — with every claim grounded in retrievable evidence and every gap stated explicitly, and that assess how likely a human-derived signal is to hold up in the lab and beyond.
This role is ideal for someone who would rather build production AI systems for translational science than only run analyses, and who has enough hands-on biology to know when a recommendation is scientifically sound and when it merely reads well. You will own the engineering of these systems end to end, from retrieval and orchestration to evaluation and deployment, and work as a peer with the scientists who act on their outputs.
Basic qualifications
Preferred technical qualifications
Preferred scientific qualifications
Also valued
Our company
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases including diabetic macular edema. BGE-102 has completed a Phase 1 SAD/MAD trial demonstrating a well-tolerated profile and potential best-in-class reductions in hsCRP and other inflammatory biomarkers in participants with obesity and elevated inflammation. Phase 2 cardiovascular risk proof-of-concept data are anticipated in H2 2026, and Phase 1b/2a diabetic macular edema proof-of-concept data are anticipated in mid 2027. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging. BioAge has been listed on Nasdaq (BIOA) since 2024. For additional information about BioAge, visit the company’s website at https://bioagelabs.com.
Our workplace
BioAge offers competitive salary, a comprehensive compensation package, and generous paid time off in addition to company-observed holidays. We provide comprehensive health and wellness benefits (medical, dental, and vision insurance) and a 401(k) retirement savings plan with matching employer contributions, and we support families through childcare and fertility benefits. We also pride ourselves in giving employees many opportunities for career development, including a generous annual budget for continued learning and a dedication to training and skill development. Many positions (including this one) are remote, allowing our team members to work from anywhere. The salary for this role is expected to be approximately $150,000 - $185,000, depending on experience. We are open to the concept that different experience levels add value to the team in different ways, and therefore will consider a variety of experience and offer commensurate pay.
At BioAge, we embrace diversity and differences while we learn from each other, and we believe that every team member has an important role to play. We are an equal opportunity employer. BioAge prohibits discrimination and harassment of any type and affords equal employment opportunities to employees and applicants without regard to race, color, religion, sex, national origin, disability status, protected veteran status, or any other characteristic protected by law. BioAge conforms to the spirit as well as to the letter of all applicable laws and regulations.
[]
Clinical-stage biotech developing aging-targeted therapeutics
BioAge Labs develops therapies for age-related diseases by using a human-first discovery platform that maps human aging and translates those insights into a portfolio of drugs. Its approach starts from human aging profiles to identify drug targets and then creates medicines that prevent or treat diseases of aging, with the aim of extending healthy lifespan. The company operates in the clinical stage, developing longevity-focused therapeutics that can be sold to healthcare providers and patients as they progress through trials and gain approvals. What sets BioAge Labs apart is its focus on human aging biology as the starting point for drug development and its goal to address aging itself, not just individual diseases, providing a path to broader healthspan extension compared to traditional disease-focused approaches. The overarching goal is to deliver longevity medicine that delays or prevents age-related decline and improves healthspan for patients.
Explore more opportunities at BioAge Labs